Alzheimer’s Therapy market size was valued at USD 4,211.8 million in 2022 and is expected to grow at a 16.3% CAGR from 2023 to 2029. Alzheimer’s disease is a neurological disorder that causes the brain to shrink and brain cells to die. Alzheimer’s disease is the most common cause of dementia that leads to continuous decline in thought process, social and behavioural skills that affect the ability of a person to function independently. The early symptoms of Alzheimer’s disease include forgetting recent events or conversations. An Alzheimer diseased patient portal will have a severe memory loss and lose the ability to carry out everyday tasks as the disease progresses. The rise in prevalence of Alzheimer’s disease in emerging countries and developed countries is expected to drive the market growth in the forecasted period. In addition, the increase in occurrence of Alzheimer’s disease across the globe by the diagnosis of patients has boosted the Alzheimer’s disease therapy. According to Alzheimer’s Association, approximately 6 million people are living with Alzheimer’s in USA and it can be expected to reach 13 Million by 2050. Moreover, availability of various drug class for Alzheimer’s disease is expected to boost to growth of Alzheimer’s disease market. The increase in number of Alzheimer disease cases thus increases the demand for Alzheimer’s therapy. Advancement in the treatment, and drug discovery techniques drives the demand for Alzheimer’s therapy across the globe. Rising investment in research and development of innovative drugs by the key pharmaceutical companies is expected to fuel the growth Alzheimer’s disease market. In addition, the presence of pipeline drugs in the clinical trial phase is expected to boost the growth of Alzheimer’s market in a significant rate in the forecasted period. Geographically, North America region held the major market share in 2022 and is expected to dominate the global Alzheimer’s therapy market in the forecasted years.

Alzheimer’s Therapy Market Key Developments:
In October 2022, Cyclo Therapeutics Inc. commenced their phase II study of their pipeline drug ‘Trappsol Cyclo’.
In January 2023, the U.S. Food and Drug Administration approved Eisai, Inc.’s Leqembi via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.